Monte Rosa Therapeutics, Inc. GLUE

11.77 0.05 0.43% as of 25 Sep
Market cap
$999.9M
P/E
0.0×

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income
(161.12) (130.01) (38.63) 20.95

+8 more TTM periods

Depreciation & Amortization
8.13 8.34 8.36 8.33
Non Cash Items (Other)
18.25 17.42 16.66 16.04
Accounts Receivable Change
— (8.62) (15.82) —
Accounts Payable Change
1.15 1.54 (13.71) 10.21
Change in payables and accrued liability
11.43 6.75 7.85 2.81
Change in other assets and liabilities
105.09 81.30 3.67 90.80
Operating Cash Flow
(24.07) (14.67) (22.80) 149.14
Capital expenditures
(8.01) (4.98) (4.70) (4.12)
Short Term Investments Change (Net)
(308.78) (257.62) (97.13) (63.55)
Investing cash flow
(316.78) (262.60) (101.83) (67.66)
Equity Repurchase (Common, Net)
362.36 359.52 30.71 (45.02)
Other financial activities
(0.48) 45.88 46.37 —
Financing cash flow
361.52 358.67 30.35 1.34
Change in Cash
20.66 81.40 (94.28) 82.81
Beginning Cash
134.84 134.84 229.12 229.12
Ending Cash
155.50 216.23 134.84 311.93
Stock Based Compensation
20.59 19.52 18.87 19.03
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
110.67 89.59 (9.19) 103.83
Investments Change (Net)
(308.78) (257.62) (97.13) (63.55)
Issuance/Purchase of Shares
362.36 359.52 30.71 (45.02)

Fold the line items

In millions of $ except per-share values · columns are period end dates